Extending the US Food and Drug Administration's Postmarket Authorities

Area of Science:

• Drug regulatory affairs
• Pharmaceutical policy
• Clinical trial design

Background:

• The US Food and Drug Administration (FDA) utilizes significant regulatory flexibility in drug approval, often permitting market entry based on limited evidence of benefit.
• This flexibility has not been consistently matched by robust postmarket safeguards to confirm drug efficacy or address uncertainties.
• Concerns exist regarding the adequacy of postmarket surveillance and the timely withdrawal of drugs lacking confirmed benefits.

Purpose of the Study:

• To explore opportunities for the FDA to enhance its authority in requiring postmarket efficacy studies.
• To evaluate the potential for utilizing expedited withdrawal procedures for drugs approved with substantial residual uncertainty.
• To assess these opportunities beyond the existing accelerated approval pathway.

Main Methods:

• Analysis of FDA's current regulatory approaches to drug approval standards.
• Review of postmarket shortcomings and existing statutes governing postmarket study requirements.
• Examination of recent legislative reforms and agency actions related to accelerated approval.

Main Results:

• The FDA possesses the legal authority under the Food, Drug, and Cosmetic Act to extend postmarket efficacy study requirements and expedited withdrawal procedures to drugs approved with significant residual uncertainty.
• This includes drugs supported by single pivotal trials, aligning with core accelerated approval authorities.
• Effective implementation requires well-designed, timely postmarket studies and decisive withdrawal actions when benefit is not confirmed.

Conclusions:

• Current FDA drug approval practices can leave patients, clinicians, and payers uncertain about a drug's true benefit.
• Policy decisions favoring early market access over evidentiary certainty necessitate stronger postmarket safeguards.
• The FDA can leverage its existing legal framework to implement more expansive postmarket safety and efficacy evaluations.